Literature DB >> 18220551

The clinical applications of intranasal opioids.

Katherine Shelley1, Michael James Paech.   

Abstract

Opioids are widely used in all fields of pain management and may be delivered by a number of routes of administration. The intranasal administration of opioid is a convenient route of transmucosal drug delivery that has received limited attention. Potential advantages compared with parenteral or oral administration include avoidance of painful injection, avoidance of risks associated with intravenous access, rapid onset and titration to effect, good bioavailability, and high levels of acceptability and familiarity to patients. These features also lend themselves to the benefits of patient-controlled delivery systems and commercially available devices are described. In this paper we briefly consider the relevant pharmacology of intranasal drug delivery; opioid drugs and formulations; and delivery devices used clinically for intranasal administration. We review the clinical applications of intranasal opioid analgesia. These have included use for in-hospital pain management in adult and paediatric populations, in the emergency department, perioperatively and in burns units. Out-of-hospital use has included palliative care and paramedic use during retrieval and transfer to hospital. Many small trials suggest that intranasal opioids play a useful role in pain management, but large clinical trials are needed to better define advantages, safety and acceptability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220551     DOI: 10.2174/156720108783330989

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  11 in total

1.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 2.  [Cancer breakthrough pain. Indications for rapidly effective opioids].

Authors:  J Kessler; H J Bardenheuer
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

3.  Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

Authors:  M R Lofwall; D E Moody; W B Fang; P A Nuzzo; S L Walsh
Journal:  J Clin Pharmacol       Date:  2011-05-24       Impact factor: 3.126

4.  An open-label randomised controlled trial on the efficacy of adding intranasal fentanyl to intravenous tramadol in patients with moderate to severe pain following acute musculoskeletal injuries.

Authors:  Keng Sheng Chew; Abdul Hafiz Shaharudin
Journal:  Singapore Med J       Date:  2016-05-19       Impact factor: 1.858

Review 5.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 6.  Management of pain in the elderly at the end of life.

Authors:  Eric Prommer; Brandy Ficek
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

7.  Pediatric Sedation and Analgesia Outside the Operating Room: Combining Intranasal Fentanyl and Inhaled Nitrous Oxide.

Authors:  Julia Hoeffe; Regina G Vogel; Roland A Ammann
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

8.  Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice.

Authors:  Yong Zhang; Roberto Picetti; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2008-09-10       Impact factor: 7.853

9.  Intranasal fentanyl for pain control: current status with a focus on patient considerations.

Authors:  Eric Prommer; Lisa Thompson
Journal:  Patient Prefer Adherence       Date:  2011-03-18       Impact factor: 2.711

10.  Evaluation of a clinical protocol using intranasal fentanyl for treatment of vaso-occlusive crisis in sickle cell patients in the emergency department.

Authors:  Hugo Paquin; Evelyne D Trottier; Yves Pastore; Nancy Robitaille; Marie-Joelle Dore Bergeron; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2019-03-07       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.